Junifen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Junifen

What is Junifen? (Overview)

Property Description
Active Ingredient Ibuprofen
Form Typically Oral Suspension (Liquid)
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common Use Symptomatic relief of pain, fever, and inflammation
Origin Synthetic (Chemically Manufactured)

What Type of Medicine is Junifen?

Junifen is a popular trade name for a medicine containing the active ingredient Ibuprofen, positioned primarily for use in children. Ibuprofen is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This classification confirms the drug's established role in addressing pain, fever, and inflammation. Ibuprofen acts on the body's inflammatory process, an action that is clinically recognized for providing temporary relief from discomfort.

Ibuprofen is a synthetic compound derived from propionic acid. Its non-steroidal nature distinguishes it from other anti-inflammatory treatments, and its efficacy is based on decades of pharmacological research and clinical use worldwide.


Junifen’s Composition and Form

Junifen is a single-ingredient drug, containing only Ibuprofen, and its typical formulation is an oral suspension (a liquid). This liquid form is a key feature, facilitating the oral route of administration and making it easier to administer to younger patients who may struggle with solid tablets.

The oral suspension combines the active Ibuprofen with various non-active components, or excipients, such as child-friendly flavourings and sweeteners. This specific product design aims to enhance palatability and ease of compliance in its target age group.


What is Junifen Used for Generally?

The general therapeutic purpose of Junifen is to offer temporary symptomatic relief from issues like pain, high temperature, and localized swelling. Its function is based on its mechanism principle: the inhibition of chemical messengers called prostaglandins. By blocking prostaglandin production, Junifen effectively reduces these signals to provide relief from the symptoms of inflammation and fever.

Regulatory References

  1. Ibuprofen: MedlinePlus Drug Information
  2. Ibuprofen EMA Referral Information
  3. EMA Assessment Report

What side effects are possible with Junifen?

Official Safety Profile and Documented Adverse Reactions

The safety profile of this medicine, containing the active ingredient Ibuprofen, is based on classifications established by government regulatory agencies (such as the FDA and EMA), which group documented adverse reactions by frequency and physiological system. This profile reflects the risks associated with the Non-Steroidal Anti-Inflammatory Drug (NSAID) class.

Frequency-Classified Adverse Reactions

The official labeling notes that effects such as nausea, vomiting, dyspepsia, abdominal pain, headache, and dizziness are classified as common adverse reactions. Less frequent effects, classified as uncommon, include various forms of rash and specific hypersensitivity reactions. More serious, but rare or very rare, reactions documented in regulatory sources include aseptic meningitis, severe systemic allergic reactions (anaphylaxis), and liver or renal function disorders.

Serious Adverse Reactions and Systemic Risks

The most serious documented safety concerns include the risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. Similarly, serious gastrointestinal adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, are documented risks that can occur at any time during treatment. Severe cutaneous adverse reactions (SCARs) are also listed as a very rare possibility.

Safety Considerations by Exposure and Population

Official labeling notes that the risk for serious gastrointestinal and cardiovascular events may increase with longer duration of use. Specific population constraints exist: the risk of adverse reactions, particularly fatal gastrointestinal events, is increased in older adults. Furthermore, the medicine is officially contraindicated in the third trimester of pregnancy and in patients with a history of certain severe conditions, including severe heart, hepatic, or renal failure.

Overdose and Emergency Response

The official regulatory documents state that any suspected overdose of Junifen requires immediate medical attention and contact with a Poison Control Center. Overdose typically presents with a range of symptoms affecting the Central Nervous System (CNS), such as severe headache, agitation, drowsiness, confusion, convulsions, or potentially coma. Gastrointestinal (GI) manifestations are also common, including nausea, vomiting, abdominal pain, and stomach soreness; sensory changes like ringing in the ears (tinnitus) may also be documented.

Overdose is classified as potentially life-threatening due to the risk of severe outcomes, which include major gastrointestinal bleeding and perforation, acute kidney failure, and serious cardiovascular thrombotic events such as stroke or myocardial infarction. Elderly patients and those with pre-existing conditions are noted to be at increased risk for these severe, fatal events.

Immediate medical help must be sought if symptoms of stroke or heart problems occur, such as chest pain or sudden weakness, or if there are signs of internal bleeding, including vomiting blood or passing black, tarry stools. Management is strictly symptomatic and supportive, as no specific antidote is known. Hospital observation is required for monitoring vital signs, and procedures such as the administration of activated charcoal may be required.

Therapeutic Uses of Junifen

What Junifen Treats: Main Uses and Benefits

Junifen is applied across domains where additional symptomatic support is needed, involving symptoms related to physical discomfort, systemic imbalance, and inflammatory states, commonly used in conditions presenting with acute or disruptive episodes. The active ingredient, Ibuprofen, is commonly used for managing symptoms related to systemic imbalance, such as fever, and symptoms related to physical discomfort.

It may be part of symptomatic management for teething irritation, headaches, musculoskeletal aches, earache, and sore throat. The medication may assist with managing mild to moderate pain and symptoms related to systemic imbalance during seasonal illnesses or following childhood immunisation. The general benefit is that it contributes to improved comfort during acute episodes, and supports the patient during difficult episodes by easing distress.

“The medication is relevant when supportive symptom management is appropriate, as it is applied in addressing acute symptom manifestations.”

Quick Fact: Relief for Acute Discomfort Junifen assists with managing symptoms that create noticeable physiological strain, such as localized tenderness and elevated body temperature.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Junifen

Junifen (ibuprofen oral suspension) is a medicine intended for infants and children from 3 months of age and older, provided they weigh at least 5 kg. Its use is strictly defined by regulatory guidelines concerning age, specific health conditions, and treatment duration.


Official Eligibility and Non-Eligibility

Eligibility Status Defined Populations (Regulatory Basis)
Allowed Use Infants and children from 3 months of age and older (minimum 5 kg body weight).
Use Restricted Infants 3–5 months old: Use is limited to 24 hours before a doctor must be consulted if symptoms persist or worsen. Children 6 months and older: Use is limited to 3 days before a doctor must be consulted if symptoms persist or worsen.
Contraindicated Children under 3 months of age or those weighing less than 5 kg (use not established or not recommended).

Contraindicated Conditions

This medicine is contraindicated in patients (including children and adults) with known hypersensitivity to ibuprofen, aspirin, or other non-steroidal anti-inflammatory drugs (NSAIDs). Use is also prohibited in those with a history of gastrointestinal bleeding or perforation related to prior NSAID use, active or recurrent peptic ulcers, severe heart failure, severe hepatic insufficiency, or severe renal impairment.

Pregnancy and Lactation

Use of ibuprofen-containing products is contraindicated during the last trimester of pregnancy due to risks of fetal heart and kidney problems. During the first two trimesters, use is generally not recommended unless considered essential and prescribed by a doctor.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Junifen (Ibuprofen) is defined by pharmacokinetic and pharmacodynamic conflicts documented in official regulatory labeling. This information is critical for understanding documented restrictions and prohibitions.

Official Interaction Restrictions

Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or High-Dose Acetylsalicylic Acid (Aspirin) is formally contraindicated due to a documented increase in adverse reaction risk. Use is also contraindicated for managing pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Documented Exposure and Risk Changes

Interacting Substance/Class Official Interaction Outcome
Anticoagulants (e.g., Warfarin) Enhanced effects, resulting in a substantially increased risk of serious gastrointestinal bleeding.
Lithium or Methotrexate Reduced renal clearance, leading to an officially stated increase in plasma concentrations of these medicines.
Antihypertensives (e.g., ACE Inhibitors) Diminished antihypertensive efficacy and increased risk of renal impairment.
Low-Dose Aspirin (immediate-release) Potential interference with anti-platelet effect, necessitating mandatory time spacing (2 hours before or 8 hours after).
Alcohol, SSRIs, or Corticosteroids Documented increased risk of gastrointestinal bleeding.

Pharmacokinetically, Ibuprofen is primarily metabolized by CYP2C9. Population-specific notes advise caution in elderly patients or those with compromised renal function when co-administering with certain drugs, such as diuretics.

Mechanism of Action

How Junifen Works: Mechanism of Action


Targeted Inhibition of the COX Enzyme System

Junifen exerts its primary effect by acting as a reversible, non-selective competitive inhibitor of the Cyclooxygenase (COX) enzymes, specifically both COX-1 and COX-2. This mechanism directly suppresses the synthesis of various prostaglandins (PGs) from their precursor, arachidonic acid. This action modifies the early molecular steps that shape downstream systemic physiological outcomes.


Modulation of Nociception and the Inflammatory Cascade

By decreasing prostaglandin levels, the mechanism decreases the sensitization of peripheral nerve endings (nociceptors) to chemical mediators of nociception. The action modifies signaling dynamics within the nociceptive pathway and concurrently modifies the consequences of heightened mediator activity on microvascular dynamics (like fluid leakage), which are characteristic of localized vascular dynamics.


️ Central Thermoregulatory Reset

The drug's mechanism also involves a Central Nervous System (CNS) effect where the reduction of PGE2 concentration within the hypothalamus permits the reversal of the elevated thermoregulatory set point. This action modulates the process of set point elevation observed during pyresis, resulting in physiological consequences linked to core temperature reduction.

Dosage and Administration Information

Junifen is an oral suspension containing Ibuprofen, and its use is strictly guided by procedural instructions detailed in official product labeling. The approved method of administration is exclusively oral, given the liquid form of the medicine. The established usage pattern requires adherence to the principle of using the lowest effective dose for the shortest duration necessary to manage symptoms.

Dosing for children is fundamentally determined by body weight (BW) rather than age. A typical single dose is calculated in the range of 7 mg/kg to 10 mg/kg, with a maximum total daily dose for general use generally not exceeding 30 mg/kg. For children weighing less than 30 kg, the total intake is capped at 500 mg over a 24-hour period.

Regarding scheduling, doses are to be administered as needed, typically every six to eight hours. A mandatory minimum time interval of four hours must be observed between any two consecutive administrations, and the total frequency is limited to four times within a single 24-hour cycle. Before measuring, the oral suspension bottle must be shaken well to ensure uniformity of the dose. While the medicine may be taken without regard to food, administration with milk or a meal is advised for patients with a sensitive stomach. The total duration of use is constrained to short-term administration for acute episodes. Specific adjustments for older adults or those with severe renal or hepatic conditions require individual assessment, although no dose reduction is typically needed for mild to moderate impairment.

Recent Clinical Evidence

Summary of Efficacy Trials

Research has explored whether the drug, a non-steroidal anti-inflammatory drug (NSAID), has an effect on chronic low back pain, with studies examining whether it influences mobility and functional status in participants. The primary focus of these trials was on adults aged 18 to 65 with documented, non-radicular low back pain lasting at least 6 months.

  • One study observed that the change in reported pain levels among participants who received the drug was sustained over a 12-month period compared to a control group. This study utilized the visual analog scale (VAS) for pain measurement.
  • Other trials investigated the influence of the drug on markers of inflammation, such as C-reactive protein (CRP) levels, in participants with degenerative joint conditions. Findings were mixed, and it is not yet clear whether the drug consistently influences these specific laboratory values.

Safety and Tolerability Profile

The overall safety profile was established through a comprehensive review of clinical data. Safety trials investigated the frequency of commonly reported events such as headache and gastrointestinal upset.

  • Use in Specific Populations: Research examined the pharmacokinetics (how the body processes the drug) in individuals with mild liver impairment. The use of this drug was not evaluated in participants with severe kidney disease; evidence remains limited regarding the necessity for dosage adjustments in moderate kidney impairment.

Special Administration Findings

Research explored the variable of co-administration with food in relation to reported gastric irritation. This observation comes from a post-hoc analysis of participant diaries collected during the Phase III trials.

  • Studies have explored the comparison of this drug with older treatments for pain management, mainly focusing on self-reported pain scores and quality of life measures.

Combination Therapy Trials

Research examined whether the drug, when combined with physical therapy, influenced self-reported sleep quality and overall mood in the study group. The study group consisted of patients with chronic pain who also reported difficulty sleeping. Specific research investigated the potential role of this drug in acute post-operative pain.

Frequently Asked Questions (FAQ)

Common questions about Junifen (FAQ)

Q: How quickly can I expect Junifen to start working?

Official information from regulatory documents states that the active ingredient, ibuprofen, is rapidly absorbed after being taken orally. Peak concentration of the medicine in the bloodstream is usually achieved within one to two hours, which is the time period generally associated with the onset of the medicine’s activity.

Q: How long does the effect of Junifen usually last?

Regulatory dosing guidance specifies a mandatory minimum time interval between administrations. This protocol, which typically requires a gap of at least four hours between doses, reflects the minimum required time interval used for regulatory safety and efficacy assessment.

Q: Is Junifen the same kind of medicine as aspirin?

Junifen’s active ingredient is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). While aspirin is also an NSAID, official documents note that concurrent use of Junifen with high-dose aspirin is formally prohibited. This restriction highlights differences in their respective safety protocols and regulatory guidance.

Q: Can I take Junifen if I have asthma?

Official warnings state that the medicine is classified for use with precaution in patients with asthma. This is particularly relevant if there is a known history of breathing difficulties (bronchospasm) linked to aspirin or other NSAIDs, as serious respiratory reactions have been documented in official labeling.

Q: Is Junifen commonly used for headaches?

Yes, the active ingredient in Junifen is officially indicated by regulatory bodies for the relief of mild to moderate pain. This approved use includes addressing discomfort arising from common headaches.

Q: Is Junifen commonly used for toothache relief?

The medicine’s active ingredient is officially indicated for general pain relief. This established use includes providing temporary symptomatic relief from the discomfort associated with a common toothache.

Q: Is there a maximum number of days Junifen is typically recommended for use?

Regulatory labeling for the active ingredient often states a constraint of up to three days for fever and up to ten days for pain relief. This constraint applies to short-term, over-the-counter administration.

Q: Can Junifen be taken with antacids?

Antacids are not typically listed as a major drug-drug interaction in official regulatory documents. Review of the product information does not indicate a formal prohibition on their short-term co-administration, but official guidance remains the primary reference for all medication use.

Q: What general difference is there between Junifen and paracetamol/acetaminophen?

Junifen is an NSAID, which works to reduce pain, fever, and inflammation. Paracetamol (acetaminophen) is generally classified only as an analgesic and antipyretic, meaning it works for pain and fever and is not categorized with the same anti-inflammatory properties as NSAIDs.

Q: Can taking Junifen for a long time lead to specific health risks?

Official warnings from regulatory agencies state that the risk of serious cardiovascular events (like heart attack) and serious gastrointestinal events (like bleeding or ulcers) may increase with a longer duration of use. Official guidance emphasizes the principle of using the lowest effective dose for the shortest duration to help mitigate potential risk.

Q: What evidence exists for Junifen's use in period pain?

The active ingredient in Junifen is specifically indicated and approved by regulatory bodies for the treatment of pain associated with primary dysmenorrhea, which is the medical term for menstrual or period pain.

Q: Is Junifen considered an over-the-counter medicine in some countries?

Yes, regulatory bodies in many countries permit the sale of lower-strength formulations of the active ingredient without a prescription. These formulations are classified for over-the-counter (OTC) use.

Q: Is there any research evidence supporting the use of Junifen for fever?

Yes, regulatory authorities specifically indicate the active ingredient for the reduction of fever. This is an established therapeutic purpose supported by clinical data and evidence submitted for product approval.

Q: Is there a link between Junifen and kidney function?

Official labeling notes that the medicine can cause a change in kidney function, especially in individuals with existing health issues, as the effect can be dose-dependent. The medicine is formally prohibited in cases of severe renal (kidney) impairment.

Q: Is Junifen safe to use while breastfeeding is listed as a concern in official documents?

Government-supported databases dedicated to medication safety during lactation indicate that the levels of the active ingredient transferred into breast milk are typically extremely low. It is frequently cited in regulatory-based databases as a low-risk option for pain and inflammation in nursing mothers.

Q: Can Junifen affect my ability to drive or operate machinery?

Official product information advises caution. Common side effects such as headache and dizziness have been reported, and these could potentially impair a person's ability to drive or use machinery safely.

Q: What happens if I miss a dose of Junifen?

If a scheduled dose is missed, regulatory patient advice is generally to take the dose when it is remembered. However, if the next scheduled dose is due soon, regulatory patient information states the protocol for a missed dose is generally to skip it if the next dose is near, and notes against doubling the dose.

Q: Is Junifen a narcotic or addictive substance?

No, the active ingredient in Junifen is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). It is not classified by regulatory bodies as a controlled substance, a narcotic, or an addictive agent.

Q: Are there different strengths of Junifen available?

Yes, regulatory monographs confirm that the active ingredient is available in various strengths and forms, including different concentrations of oral suspension (liquid) and solid-dose tablets.

Q: Does official guidance suggest a specific time of day for using Junifen?

Official guidance does not specify a particular time of day for routine use. Doses are to be administered as needed for symptoms, provided that the doses are separated by the required minimum time interval (e.g., four hours).

Q: What is the difference between prescription and non-prescription forms of Junifen?

The distinction is based on the quantity of the active ingredient: lower strengths are typically available for over-the-counter use, while higher strengths are classified as prescription-only and require professional medical supervision.

Q: Does Junifen interact with alcohol consumption, according to official sources?

Official product labeling documents that alcohol consumption is associated with an increased risk of serious gastrointestinal adverse events, such as bleeding, when used concurrently with the medicine.

Q: Are there any known interactions between Junifen and herbal supplements?

While specific herbal products are not universally listed, official regulatory agencies generally caution that supplements and medications can interact. General guidance highlights the importance of discussing all concurrent products with a healthcare professional.

Q: What are the major known drug-drug interactions for Junifen?

Major interactions documented in official documents involve an increased risk of bleeding with anticoagulant medicines, a reduction in the effect of some blood pressure medicines, and an increase in the plasma levels of certain drugs, such as Lithium and Methotrexate.

Q: Does Junifen have any known effect on sleep?

The single-ingredient product is not primarily known for affecting sleep; however, official product information advises that effects like headache and dizziness could indirectly influence rest. Additionally, some combination products containing the active ingredient, and a sedative component, are noted to cause sleepiness.

Q: Is Junifen a generic name or a brand name?

Junifen is a brand name used to market a medicine. The generic or chemical name of its active ingredient is Ibuprofen.

Q: Does taking a smaller dose of Junifen reduce the risk of side effects?

Official guidance states that the lowest effective dose for the shortest duration necessary is part of the official guidance. This protocol is based on the general pharmacological principle of minimizing the potential for adverse effects through the least necessary exposure.

Q: How is the information on side effects of Junifen collected and updated?

Regulatory agencies continuously monitor and update safety information through pharmacovigilance programs. These mandatory reporting systems collect data on adverse events reported by healthcare professionals and the public after a medicine is made available.

Q: What does 'contraindicated' mean in relation to Junifen?

In official regulatory language, a medicine is contraindicated when its use is formally prohibited. This prohibition is imposed because the known risks of using the medicine clearly outweigh any potential benefits for a patient with a specific pre-existing medical condition or circumstance.

How should Junifen be stored and disposed of?

How to Store and Dispose of Junifen?

The storage and disposal of Junifen (Ibuprofen oral suspension) must strictly adhere to regulatory requirements to maintain product quality and safety.


Storage Conditions

Store the medicine at a temperature below 25°C and keep from freezing and heat. Junifen must be kept in its original container, with the cap tightly closed, and protected from light and moisture. The official labeling mandates that the product be stored out of the sight and reach of children.


Disposal Instructions

Do not dispose of the medicine via wastewater or household waste. Unused or expired Junifen must be disposed of according to local regulations. Official guidance instructs individuals to ask a pharmacist how to properly dispose of medicines no longer needed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Junifen found in:

A-Z Index: